| Functions |
Neurologist specialized in movement disorders, Professor of clinical and fundamental pharmacology |
| Expertises and fields of research |
Development of new therapeutic strategies (symptomatic and disease-modifying) and of biomarkers in Parkinson's disease and amyotrophic lateral sclerosis using translational studies, clinical studies and phase I and II therapeutic trials |
| Number of publications |
> 200 |
| Number of national and international projects |
- 30 studies including 14 multicenter trials and 14 as coordinator (10 ongoing projects), 4 project funded by the European commission (H2020) including 2 in neurosciences (iron, ferroptotic cell death), 1 large European clinical trial FAIRPARK-2 http://www.fairpark2.eu/people/david-devos and 1 on Covid-19 diagnostic.
- 6 patents leading to 3 industrial transfers with co-foundation of 3 start-ups (InBrain Pharma for brain perfusion, InVenis Biotherapies for platelet-based biotherapies and Cordial-IT for diagnostic tools).
|
| Some key projects |
- PREDISTIM: Multicentric study of the predictive factors of the therapeutic response to subthalamic stimulation on the long-term quality of life and study of the pharmacogenetic factors of the L-dopa treatment response in Parkinson’s disease Protocol ID: 2013-A00193-42; ClinicalTrials.gov: NCT02360683
- PULSE: Multicentric study of the Pronostic valUe of biomarkers in amyotrophic Lateral Sclerosis & Endophenotypic study Protocol ID: 2013-A00969-36; ClinicalTrials.gov: NCT02360891
- FAIR-PARK-II: European multicentric study of Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease: a multicentre, parallel-group, placebo-controlled, randomized clinical trial of deferiprone; ClinicalTrials.gov Identifier: NCT02655315 http://www.fairpark2.eu/
- FAIR-ALS-II: Conservative Iron Chelation by Deferiprone as a Disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial on 240 patients. Protocol ID: 2017-003763-35; ClinicalTrials.gov: NCT03293069
- PACTE-I: Potentiation of cognitive functions in healthy elderly by association of methylphenidate and cognitive training: Proof of concept study in order to develop a synergic symptomatic treatment of cognitive disorders before dementia. Protocol ID: 2015_81; ClinicalTrials.gov: NCT03280251
- PRION-IRON: European funds from (Network of Centres of Excellence in Neurodegeneration (CoEN) (PRION like propagation of synucleinopathy associated with ferroptosis, the IRON dependent cell death): to develop new therapeutic strategies against ferroptosis
- PARKINSUN: Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care. Protocol ID: 2018_74 ; ClinicalTrials.gov: NCT04179695
- DIVE: Evaluation of the safety and efficacy of continuous dopaminergic stimulation by intracerebroventricular administration of anaerobic dopamine conserved in Parkinson's disease at the motor fluctuation stage. Trial Registration: Protocol ID: 2018_49; French Ethical Committee; 2020-000155-12; ClinicalTrials.gov ID: NCT04332276, academic patents with industrial transfer with a start-up creation: InBrain Pharma https://www.inbrainpharma.com/
- GIFT project (biothérapie: Growth factor preparations from platelets & neuroprotective strategies) 3 patents and one industrial transfer in progress with start-up creation InVenis biotherapies.
- CorDial-1 patent (methods for detecting a target in a sample using mutated nanobodies) with one industrial transfer in progress with start-up creation CorDial-IT
|
